Prospector
Profile
07.1296
|
| |
| Viridax Corporation |
NAICS |
541710 |
| 13176 N. Dale Mabry Highway
Tampa, Fl 33618 |
Description |
Biotechnology |
| (202) 470-6819 |
Employees |
1 |
| http://www.viridax.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-0.4960 |
| |
Assets |
(mil) |
1.9020 |
| |
Liability |
(mil) |
0.1750 |
| |
(for the year ended 2007-04-30) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
Earl M. Cohen CPA PA expressed substantial doubt about the ability of Viridax Corporation to continue as a going concern after auditing its financial statements. The auditor points out that the Company is still in the development stage with an accumulated deficit of $1,068,866, a working capital deficiency of $151,102 and, since inception, a negative cash flow from operations of $767,493.
|
| |
|
Intellectual Property:
The Company's Staphylococcal Bacteriophage stock represents the core intellectual property and biological materials of Viridax, and is the retained source material for the Company’s first series of products for the treatment of ophthalmic, respiratory, systemic and topical Staph infections in humans. The Company has applied for registration of the trademark Viridax™. [SEC Filing 10-KSB 08-13-07]
|
| |
|
Description:
Viridax is a biopharmaceutical discovery and development company formed to expedite the commercialization of new technologies and products for the treatment of bacterial infectious diseases, especially antibiotic-resistant infections.
|
| |
|
Officers:
Richard C. Honour (Chair, Pres. & CEO); Kenneth E. Lehman (CFO & Dir.); Ledyard H. DeWees (Sec.); Michael C. Maloney (Dir.); Javid Sheikh (Dir.)
|
| |
|
Auditor:
Earl M. Cohen CPA PA
|
| |
|
Securities:
24,338,090 common shares outstanding as of April 30, 2007.
|
| |
| |
| |
| return to main page |
